Transition Therapeutics Announces Fiscal 2007 Year End Financi...(2729422 1097521 -----------------...),Health

-------------------------------------------------------------------------

Net loss for the year (16,961,790) (23,018,090)

-------------------------------------------------------------------------

Deficit, beginning of year,

As originally stated (69,504,180) (46,486,090)

Adjustment for change in accounting

policy related to research inventory (3,225,599) -

-------------------------------------------------------------------------

Deficit, beginning of year, as restated (72,729,779) (46,486,090)

-------------------------------------------------------------------------

Deficit, end of year (89,691,569) (69,504,180)

-------------------------------------------------------------------------

-------------------------------------------------------------------------

Basic and diluted net loss per common share $(0.87) $(1.53)

-------------------------------------------------------------------------

-------------------------------------------------------------------------

CONSOLIDATED STATEMENT OF SHAREHOLDERS' EQUITY

For the years ended June 30, 2007 and 2006

(in Canadian dollars)

Number of Share Contributed Stock

Shares Capital Surplus Options

-------------------------------------------------------------------------

$ $ $

Balance, July 1, 2005 13,344,007 77,254,351 2,811,966 743,628

Share issued for

purchased assets of

Protana, net 222,222 1,184,569 - -

Issued pursuant to

bought deal

financing, net 1,730,556 9,648,600
'/>"/>